AI-enabled pathology solutions company Proscia more than doubled its growth in 2024, it has announced. The company enters 2025 having cemented its leadership position, with life sciences organisations and diagnostic laboratories increasingly deploying its Concentriq enterprise pathology platform to advance the next novel therapies and diagnostics.
“2024 was a breakout year for Proscia,” said David West, CEO. “And the momentum only continues to accelerate. There’s a new wave of demand as pathology and AI propel precision medicine forward. Our traction has proven that we can rewire pathology for this paradigm shift and help our customers remain at the forefront for their scientists, pathologists, and patients.”
Proscia’s clinical customers diagnosed 2.4 million patients on Concentriq in 2024. The company expects this volume to more than triple this year, in part as it continues to grow its global network of diagnostic laboratories through distribution partnerships with Agilent Technologies and Siemens Healthineers.
In addition to being the platform of choice for world-class organisations, Concentriq was recognised by KLAS Research on its October 2024 Emerging Solutions Top 20 for improving patient outcomes. Proscia was also ranked as the leader among 15 vendors in CB Insights’ ‘Digital pathology – general diagnostics’ and “Digital pathology – oncology diagnostics’ Execution, Strength, and Positioning market matrices.
Proscia expanded Concentriq with four new offerings for tapping into the data-rich profile of diseases like cancer contained in each pathology image. It introduced a Real-World Data (RWD) offering after a successful year-long pilot, grew its RWD business by 10x, and continues to add over 150,000 unique records per month to its RWD repository.